Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent

Core Viewpoint - The U.S. District Court for the District of Delaware upheld the jury's finding of willful infringement by Alcon and awarded Sight Sciences over $34 million in past damages, along with ongoing royalties through November 2028 [1][2]. Legal Outcome - The Court's order confirmed the jury's verdict that Alcon willfully infringed all three of Sight Sciences' asserted patents and awarded $34 million in monetary damages, which includes $5.5 million in lost profits and $28.5 million in royalty damages [2][6]. - An ongoing royalty of 10% of Hydrus revenue will be applicable until the expiration of Sight Sciences' last asserted patent on November 10, 2028 [2][6]. Company Perspective - Sight Sciences expressed satisfaction with the ruling, emphasizing the importance of its intellectual property portfolio in interventional glaucoma and its commitment to advancing glaucoma care through innovative technologies [4]. - The company anticipates recording a $5.4 million success fee related to the litigation, which will be excluded from non-GAAP adjusted operating expenses [4]. Product and Technology Focus - Sight Sciences is dedicated to developing innovative and interventional solutions for eye care, particularly in the field of glaucoma, utilizing minimally invasive techniques [5]. - The company's products include the OMNI® Surgical System and OMNI® Edge Surgical System, which are designed to reduce intraocular pressure in patients with primary open-angle glaucoma [5].